Bavarian Nordic A/SOTC Pink - Limited Information:BVNRY
- LAST PRICE7.0460
- TODAY'S CHANGE (%)0.1260 (1.8208%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close7.0300 / 6.9200
- Day Range
- 52 Week Range
- Volume892
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BVNRY |
|---|---|---|
| 09:32 ET | 250 | 7.03 |
| 09:39 ET | 100 | 7.06 |
| 09:41 ET | 150 | 7.0675 |
| 11:13 ET | 192 | 7.05 |
| 11:22 ET | 200 | 7.046 |
Apr 2, 2024
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S., from 2:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
2:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bavarian Nordic A/S | 1.6B | 7.5x | --- |
China BCT Pharmacy Group Inc | 3.8K | 0.0x | --- |
LifeVantage Corp | 80.3M | 26.7x | -16.83% |
Takeda Pharmaceutical Co Ltd | 41.6B | 36.0x | -3.20% |
Xeris Biopharma Holdings Inc | 252.0M | -3.9x | --- |
Procaps Group SA | 307.7M | 5.2x | --- |
Company Information
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
Contact Information
- Headquarters
- Philip Heymans Alle 3HELLERUP, Denmark 2900
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Luc Debruyne
- President, Chief Executive Officer
- Paul Chaplin
- Deputy Chairman of the Board
- Anders Pedersen
- Executive Vice President, Chief Financial Officer
- Henrik Juuel
- Executive Vice President, Chief Operating Officer
- Russell Thirsk
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $1.0B |
Shares Outstanding | 234.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $0.93 |
Book Value | $6.35 |
P/E Ratio | 7.5x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | 5.5x |
Operating Margin | 21.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
